Q3 Earnings Estimate for NRIX Issued By Leerink Partnrs

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Nurix Therapeutics in a report released on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.96) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q4 2025 earnings at ($1.00) EPS, FY2025 earnings at ($3.79) EPS and FY2026 earnings at ($3.32) EPS.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

A number of other research firms have also recently weighed in on NRIX. Stifel Nicolaus lifted their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lowered their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Needham & Company LLC lowered their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Leerink Partners started coverage on Nurix Therapeutics in a research note on Monday. They set a “market perform” rating and a $16.00 target price on the stock. Finally, BMO Capital Markets started coverage on Nurix Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $35.00 target price on the stock. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $30.88.

Nurix Therapeutics Stock Up 1.8 %

NRIX stock opened at $13.90 on Thursday. Nurix Therapeutics has a twelve month low of $11.90 and a twelve month high of $29.56. The stock has a market cap of $1.05 billion, a P/E ratio of -4.81 and a beta of 2.18. The business’s 50-day moving average price is $17.22 and its 200-day moving average price is $20.93.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 3,690 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the transaction, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Houte Hans Van sold 5,825 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. This represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock worth $213,449 in the last quarter. 7.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Nurix Therapeutics in the 4th quarter worth $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Nurix Therapeutics by 14.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 146,713 shares of the company’s stock worth $2,764,000 after buying an additional 18,189 shares during the period. Woodline Partners LP lifted its holdings in shares of Nurix Therapeutics by 0.5% in the 4th quarter. Woodline Partners LP now owns 338,462 shares of the company’s stock worth $6,377,000 after buying an additional 1,583 shares during the period. Velan Capital Investment Management LP bought a new position in shares of Nurix Therapeutics in the 4th quarter worth $1,844,000. Finally, Vestal Point Capital LP raised its position in shares of Nurix Therapeutics by 14.1% in the 4th quarter. Vestal Point Capital LP now owns 485,000 shares of the company’s stock worth $9,137,000 after acquiring an additional 60,000 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.